Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Brady S Moffett"'
Autor:
Brady S Moffett, Jennifer Morris, Charissa Kam, Marianne Galati, Ankhi Dutta, Ayse Akcan-Arikan
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0202439 (2018)
INTRODUCTION:Vancomycin associated acute kidney injury (vAKI) is a well known complication in pediatric patients. Identification and characterization of the incidence and risk factors for vAKI in the pediatric population would assist clinicians in po
Externí odkaz:
https://doaj.org/article/e13b3213abaa4b4f97f722c2d2410fb7
Autor:
Dawoon Jung, BPharm, Omayma A. Kishk, PharmD, Adnan T. Bhutta, MBBS, Ginny E. Cummings, CRNP, Hana M. El Sahly, MD, Manpreet K. Virk, MD, Brady S. Moffett, PharmD, MPH, MBA, Jennifer L. Morris Daniel, PharmD, Amy Watanabe, MS, Nicholas Fishbane, MSc, Karen L. Kotloff, MD, Kenan Gu, PhD, Varduhi Ghazaryan, MD, PhD, Jogarao V. S. Gobburu, PhD, MBA, Ayse Akcan-Arikan, MD, James D. Campbell, MD, MS
Publikováno v:
Critical Care Explorations, Vol 6, Iss 10, p e1159 (2024)
OBJECTIVES:. To investigate which independent factor(s) have an impact on the pharmacokinetics of vancomycin in critically ill children, develop an equation to predict the 24-hour area under the concentration-time curve from a trough concentration, a
Externí odkaz:
https://doaj.org/article/a34a6293aafe4e51a718ca5102e78dff
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Vancomycin is a glycopeptide antibacterial indicated for serious gram-positive infections. Pharmacokinetics (PK) of vancomycin have not been described in pregnant women. This study aims to characterize the PK disposition of vancomycin in p
Externí odkaz:
https://doaj.org/article/73fd39602953431b8bfedfbf8501c300
Publikováno v:
Pediatric Infectious Disease Journal. 40:993-996
BACKGROUND Historically, amoxicillin (Amoxil) has been used as a first-line agent to treat pediatric urinary tract infections (UTIs). However, emerging resistance of urinary pathogens has led to broader treatment options, such as cefdinir (Omnicef).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6242e9e105a77a706a18465a5851b459
https://doi.org/10.1097/inf.0000000000003272
https://doi.org/10.1097/inf.0000000000003272
Autor:
Ayse Akcan Arikan, Brady S. Moffett
Publikováno v:
Nephrology Dialysis Transplantation. 37:1443-1450
Background Peak severity of acute kidney injury (AKI) is associated with mortality in hospitalized pediatric patients. Other factors associated with AKI, such as number of AKI events, severity of AKI events and time spent in AKI, may also have associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70c20acfcf30f41834e82ba97795ef6
https://doi.org/10.1093/ndt/gfab219
https://doi.org/10.1093/ndt/gfab219
Publikováno v:
J Pediatr Pharmacol Ther
OBJECTIVE Our objective was to determine the incidence and risk factors for intravenous acetazolamide-associated acute kidney injury (AKI).METHODS We utilized a retrospective cohort study including patients RESULTS A total of 868 patients met study c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::826b6a1cf1b207e0b21ba37239c85764
https://doi.org/10.5863/1551-6776-26.5.467
https://doi.org/10.5863/1551-6776-26.5.467
Publikováno v:
Pediatric Critical Care Medicine. 21:e566-e571
Objectives Determine the pharmacokinetic disposition of vancomycin in the pediatric ventricular assist device population. Design A retrospective, population pharmacokinetic study. Setting Large, quaternary care children's hospital. Patients Less than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa318334e3da57590b89c918c416ee10
https://doi.org/10.1097/pcc.0000000000002349
https://doi.org/10.1097/pcc.0000000000002349
Autor:
Lara S. Shekerdemian, Ryan D. Coleman, Laura Loftis, Brady S. Moffett, Jordana Goldman, James W. Thomas, Danielle Guffey
Publikováno v:
ASAIO Journal. 66:327-331
The number of children receiving extracorporeal membrane oxygenation (ECMO) has increased substantially, and includes a growing population of children with complex underlying conditions who previously may not have been considered ECMO candidates. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e5c44036fd1506454eb27a525524c1
https://doi.org/10.1097/mat.0000000000001002
https://doi.org/10.1097/mat.0000000000001002
Autor:
Praneeth Jarugula, Ayse Akcan-Arikan, Flor Munoz-Rivas, Brady S. Moffett, Vijay Ivaturi, Danielle Rios
Publikováno v:
Antimicrob Agents Chemother
We determined optimal vancomycin starting dose regimens in infants ≤180 days of age to achieve the highest probability of target attainment with an area under the concentration-time curve for 24 h (AUC(24)) of ≥400 using population pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfec9c558caca59d9e8bedf2ef9b17d0
https://doi.org/10.1128/aac.01899-21
https://doi.org/10.1128/aac.01899-21
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(5)
The study objective was to develop a population pharmacokinetic model for busulfan to comprehensively examine drug-drug interactions in paediatric patients undergoing haematopoietic stem cell transplantation. Currently, there is limited evidence to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47820ef9258d5c9f508e361ead4a1971
https://pubmed.ncbi.nlm.nih.gov/34799882
https://pubmed.ncbi.nlm.nih.gov/34799882